Caris Life Sciences (CAI) Stock Price, News & Analysis

Company Overview

Caris Life Sciences is a precision medicine company that develops molecular profiling and artificial intelligence technologies to support cancer diagnosis and treatment decisions. Its services analyze the biological characteristics of a patient’s tumor to help physicians identify information that may guide care.

The company’s offerings include tumor profiling based on DNA and RNA analysis, as well as blood-based testing. Caris also provides molecular data and research services to biopharmaceutical companies to support drug development and the study of cancer.

Founded in 2008 by David D. Halbert, Caris is headquartered in Irving, Texas. Halbert serves as the company’s chief executive officer.

Key Stats

• Today's Range: $23.05 to $24.33
• 50-Day Range: $23.96 to $36.14
• 52-Week Range: $14.19 to $36.50
• Volume: 3.57 million shs
• Average Volume: 3.94 million shs
• Market Capitalization: $6.87 billion
• P/E Ratio: 72.61
• Dividend Yield: N/A
• Price Target: $31.18
• Consensus Rating: Moderate Buy

Caris Life Sciences Stock Analysis - MarketRank™

Caris Life Sciences scored higher than 85% of companies evaluated by MarketBeat, and ranked 49th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Caris Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 8 buy ratings, 5 hold ratings, and 1 sell rating.

Upside Potential

Caris Life Sciences has a consensus price target of $31.18, representing about 30.1% upside from its current price of $23.96.

Amount of Analyst Coverage

Caris Life Sciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 200.00%

Earnings Growth

Earnings for Caris Life Sciences are expected to grow by 200.00% in the coming year, from $0.11 to $0.33 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Caris Life Sciences is 72.61, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.24.

Price to Earnings Ratio vs. Sector

The P/E ratio of Caris Life Sciences is 72.61, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.34.

Price to Earnings Growth Ratio

Caris Life Sciences has a PEG Ratio of 7.98. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Caris Life Sciences has a P/B Ratio of 10.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.02% of the float of Caris Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Caris Life Sciences has a short interest ratio ("days to cover") of 3.98, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Caris Life Sciences has recently decreased by 15.41%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Caris Life Sciences does not currently pay a dividend.

Dividend Growth

Caris Life Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.58

News Sentiment

Caris Life Sciences has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Caris Life Sciences this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for CAI on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Caris Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Caris Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,205,419.00 in company stock.

Percentage Held by Insiders

50.00% of the stock of Caris Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Caris Life Sciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 11/04/2026
• Today: 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:CAI
• CIK: 2019410
• Web: www.carislifesciences.com
• Phone: (866) 771-8946
• Fax: N/A
• Employees: 1,846
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Caris Life Sciences: $31.18
• High Price Target: $38.00
• Low Price Target: $22.00
• Potential Upside/Downside: +30.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.33
• Trailing P/E Ratio: 72.61
• Forward P/E Ratio: 72.61
• P/E Growth: 7.98
• Net Income: -$68.09 million
• Net Margins: 9.16%
• Pretax Margin: 9.31%
• Return on Equity: 16.00%
• Return on Assets: 8.05%

Debt

• Debt-to-Equity Ratio: 0.61
• Current Ratio: 6.71
• Quick Ratio: 5.84

Sales & Book Value

• Annual Sales: $812.03 million
• Price / Sales: 8.46
• Cash Flow: $1.56 per share
• Price / Cash Flow: 15.36
• Book Value: $2.23 per share
• Price / Book: 10.74

Miscellaneous

• Outstanding Shares: 286,790,000
• Free Float: 143,393,000
• Market Cap: $6.87 billion
• Optionable: Optionable
• Beta: 0.71